Research programme: radiolabeled imaging agents- Bioverativ/ Invicro

Drug Profile

Research programme: radiolabeled imaging agents- Bioverativ/ Invicro

Latest Information Update: 12 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bioverativ; Invicro
  • Class Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Haemophilia

Most Recent Events

  • 08 Mar 2018 Bioverativ has been acquired by Sanofi
  • 24 Aug 2017 Bioverativ and Invicro agree to co-develop radiolabeled imaging technologies in USA for Haemophilia (Diagnosis)
  • 24 Aug 2017 Research in Haemophilia (Diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top